Canopy Growth Corporation (CGC, Financial) saw its stock price rise significantly by 5.20%. The stock is currently priced at $4.64 per share, with a trading volume of 4.30399 million shares and a turnover rate of 5.07%. The price fluctuation stands at 4.08%.
The recent financial report indicates Canopy Growth recorded a revenue of $48.39 million, with a net loss of $94.42 million. Earnings per share were at -$1.17, and the gross profit was $12.42 million. The company shows a price-to-earnings ratio of -0.65.
Regarding analyst ratings, among the 11 institutions that provide ratings, 9% recommend buying, 55% suggest holding, and 36% advise selling Canopy Growth stock.
Within the pharmaceutical industry, where Canopy Growth operates, the overall growth was 0.60%. Notably, stocks like Biofrontera Inc, Emergent Biosolutions Inc, and others showed significant increases, while Evoke Pharma, Inc., Emergent Biosolutions Inc., and Sunshine Biopharma Inc. exhibited higher trading activities.
Canopy Growth Corporation is headquartered in Smiths Falls, Canada. It grows and sells medical and recreational cannabis through brands like Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare under Martha Stewart CBD and vaporizers from Storz & Bickel. Canopy USA, a separate entity, holds its U.S. assets and is not included in Canopy Growth's Canadian financial statements.
